Genzyme and to-BBB Collaborate on Brain Delivery of Biologics for Neurodegenerative Diseases
Brain drug delivery company to-BBB, (Leiden, The Netherlands) has entered into a research collaboration with Genzyme Corporation (Cambridge, MA) to evaluate to-BBB?s proprietary G-Technology to enhance delivery of biologics for neurodegenerative diseases.
Brain drug delivery company to-BBB, (Leiden, The Netherlands) has entered into a research collaboration with Genzyme Corporation (Cambridge, MA) to evaluate to-BBB’s proprietary G-Technology to enhance delivery of biologics for neurodegenerative diseases.
G-Technology is designed to transport different classes of drugs across the blood-brain barrier by formulating these drugs into proprietary glutathione coated liposomes. The company has shown proof of concept in different disease models and Genzyme will now evaluate the technology in its disease models.
The disease modifying properties of biological drugs like peptides, enzymes, and antibodies have become well established in the last decades as important medicines. The treatment of brain diseases with these modern treatments is unfortunately hampered by the inability of such drugs to easily pass the blood-brain barrier.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
